The core activity of Qanatpharma is the development of new therapeutic strategies for the treatment of diseases caused by microvascular dysfunction. The company is particularly focused on researching and developing medications that improve microvascular function and alleviate the effects of diseases such as cognitive decline, hypertension, and heart failure.
AI-generated
Offering
Products & services
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
End-to-end discovery and translation platform for resistance artery research, with bioengineering, multimodal phenotyping, omics analyses, AI-supported target identification and translational research design.
Drug development (GENESiS)
Drug-discovery program for first-in-class small-molecule and biologic solutions to restore resistance artery function, with generative-AI-driven lead discovery and a partner consortium.
Clinical proof-of-concept studies
Proof-of-concept studies for clinical testing of microvascular therapies, including randomized, double-blind Phase II studies, MRI and cognitive tests, and recruitment in Toronto.
Therapy development for cerebrovascular diseases
Development of therapies for subarachnoid hemorrhage, delayed cerebral ischemia and cognitive impairment in heart failure, based on restoring cerebral autoregulation.
Knowledge
No knowledge articles yet
Once Qanatpharma AG has claimed this profile, we'll publish editorial articles and case studies here together.